Home >
Providers' Home > Clinical Care > Guidelines > HIV/Hepatitis C Coinfection Recommendations > Table 10
for Health Care Providers
Table 10. Standard Treatments for Chronic Hepatitis C in the HIV-Infected patient
Back to HIV Coinfection Recommendations
| Generic (Trade Name) | Recommended Dose | Major Adverse Effects* |
|---|---|---|
| *Adverse effects included are limited to those reported in highest frequency in placebo-controlled studies, or are of sufficient severity to warrant discontinuation of therapy and/or treatment of the adverse effect(s). Consult other references for complete listing of reported adverse effects. | ||
| Peginterferon alfa 2b-12 kD (PEG-IntronR) | Weekly dose of 1.5 µg/kg SC | Flu-like symptoms Bone marrow suppression |
| Peginterferon a-2a-40 kD (PegasysR) | Weekly dose of 180 µg/kg SC | Decrease in absolute CD4 count but not CD4% Aggravation of autoimmune disorders Neuropsychiatric symptoms Seizures Acute cardiac and renal failure Retinopathy Interstitial pulmonary fibrosis More frequent injection site reactions and neutropenia with pegylated formulations of interferon than standard interferon |
| Ribavirin (CopegusR, RebetolR) | Genotype 1: 1,000 mg daily po, if patient weight <=75 kg; 1,200 mg daily po if patient weight >75 kg | Hemolytic anemia Significant teratogen Headaches |
| Genotype 2,3: 800 mg daily po | Shortness of breath GI side-effects | |
